Trial Profile
A two-step clinical study in HIV-positive subjects to assess PENNVAX-GP with INO-9012 alone and with the addition of a PD-1 checkpoint inhibitor
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2017
Price :
$35
*
At a glance
- Drugs HIV clades A C B DNA vaccine Inovio (Primary) ; INO 9012 (Primary)
- Indications HIV infections
- Focus Proof of concept; Therapeutic Use
- 05 Apr 2017 New trial record
- 30 Mar 2017 According to an Inovio Pharmaceuticals media release, this trial will be conducted at the University of California in San Fransisco and Los Angeles.